Evidence map›Paper›PMID 18281661›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2008

Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.

Ate G J Van der Zee, Maaike H Oonk, Joanne A De Hullu, Anca C Ansink, Ignace Vergote, René H Verheijen, Angelo Maggioni, Katja N Gaarenstroom, Peter J Baldwin, Eleonore B Van Dorst and 6 more

2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyControlled Clinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 191 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 10 pooled it
33.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00773071 nacompletednot on this map

Added-value of SPECT/CT in Patients Undergoing Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) for Gynecological Cancers

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2008 to 2012Enrolled15ConditionsCervical Cancer, Vulvar CancerArmsSPECT/CT guided LM/SL
NCT04541784 nacompletednot on this mapstarted 2019, after this paper: background citation

Effectiveness of a Multidimensional Mobile App Intervention "WOMAN-PRO III" to Reduce Postsurgical Symptom Induced Distress in Patients With Vulvar Neoplasia: A Mixed Methods Project

TypeinterventionalSponsorSt.Gallen University of Applied SciencesRan2019 to 2021Enrolled18ConditionsVulvar NeoplasmArmsWOMAN-PRO III, Three counselling sessions with gynaecology-oncology nurses
3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 10 syntheses or guidelines pooled it, 792 citations in OpenAlex.

  1. European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023
    Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Minimally invasive simple hysterectomy in low-risk cervical cancer: a single-arm trial with stopping rules (ENGOT-cx23/MITO/LASH trial).International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
    Trial
  18. Trial
  19. Article
  20. [Vulvar intraepithelial neoplasia and vulvar cancer].Dermatologie (Heidelberg, Germany) · 2026
    Review

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Ate G J Van der ZeeDepartment of Obstetrics and Gynecology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands. a.g.j.van.der.zee@og.umcg.nl
Maaike H Oonk
Joanne A De Hullu
Anca C Ansink
Ignace Vergote
René H Verheijen
Angelo Maggioni
Katja N Gaarenstroom
Peter J Baldwin
Eleonore B Van Dorst
Jacobus Van der Velden
Ralph H Hermans
Hans van der Putten
Pierre Drouin
Achim Schneider
Wim J Sluiter
European Institute of Oncology · ITTarget (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the safety and clinical utility of the sentinel node procedure in early-stage vulvar cancer patients. PATIENTS AND

methodsA multicenter observational study on sentinel node detection using radioactive tracer and blue dye was performed in patients with T1/2 (< 4 cm) squamous cell cancer of the vulva. When the sentinel node was found to be negative at pathologic ultrastaging, inguinofemoral lymphadenectomy was omitted, and the patient was observed with follow-up for 2 years at intervals of every 2 months. Stopping rules were defined for the occurrence of groin recurrences.

resultsFrom March 2000 until June 2006, a sentinel node procedure was performed in 623 groins of 403 assessable patients. In 259 patients with unifocal vulvar disease and a negative sentinel node (median follow-up time, 35 months), six groin recurrences were diagnosed (2.3%; 95% CI, 0.6% to 5%), and 3-year survival rate was 97% (95% CI, 91% to 99%). Short-term morbidity was decreased in patients after sentinel node dissection only when compared with patients with a positive sentinel node who underwent inguinofemoral lymphadenectomy (wound breakdown in groin: 11.7% v 34.0%, respectively; P < .0001; and cellulitis: 4.5% v 21.3%, respectively; P < .0001). Long-term morbidity also was less frequently observed after removal of only the sentinel node compared with sentinel node removal and inguinofemoral lymphadenectomy (recurrent erysipelas: 0.4% v 16.2%, respectively; P < .0001; and lymphedema of the legs: 1.9% v 25.2%, respectively; P < .0001).

conclusionIn early-stage vulvar cancer patients with a negative sentinel node, the groin recurrence rate is low, survival is excellent, and treatment-related morbidity is minimal. We suggest that sentinel node dissection, performed by a quality-controlled multidisciplinary team, should be part of the standard treatment in selected patients with early-stage vulvar cancer.

Indexed as

Sentinel Lymph Node BiopsyAdultAgedCarcinoma, Squamous CellDisease-Free SurvivalFemaleFollow-Up StudiesGroinHumansLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesSurvival Analysis

Identifiers

PMID18281661
OpenAlexW2147322486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.